T A B L E O F C O N T E N

Main results
We identified 10 RCTs in which a total of 3753 infants participated (2804 infants participated in one large trial). Most participants were stable very preterm infants of birth weight appropriate for gestation. About one-third of all participants were extremely preterm or extremely low birth weight (ELBW), and about one-fifth were small for gestational age (SGA), growth-restricted, or compromised in utero, as indicated by absent or reversed end-diastolic flow velocity (AREDFV) in the fetal umbilical artery. Trials typically defined slow advancement as daily increments of 15 to 20 mL/kg, and faster advancement as daily increments of 30 to 40 mL/kg. Trials generally were of good methodological quality, although none was blinded.
Meta-analyses did not show effects on risk of NEC (typical RR 1.07, 95% CI 0.83 to 1.39; RD 0.0, 95% CI -0.01 to 0.02) or all-cause mortality (typical RR 1.15, 95% CI 0.93 to 1.42; typical RD 0.01, 95% CI -0.01 to 0.03). Subgroup analyses of extremely preterm or ELBW infants, or of SGA or growth-restricted or growth-compromised infants, showed no evidence of an effect on risk of NEC or death. Slow feed advancement delayed establishment of full enteral nutrition by between about one and five days. Meta-analysis showed borderline increased risk of invasive infection (typical RR 1.15, 95% CI 1.00 to 1.32; typical RD 0.03, 95% CI 0.00 to 0.05). The GRADE quality of evidence for primary outcomes was "moderate", downgraded from "high" because of lack of blinding in the included trials.
Authors' conclusions
Available trial data do not provide evidence that advancing enteral feed volumes at daily increments of 15 to 20 mL/kg (compared with 30 to 40 mL/kg) reduces the risk of NEC or death in very preterm or VLBW infants, extremely preterm or ELBW infants, SGA or growth-restricted infants, or infants with antenatal AREDFV. Advancing the volume of enteral feeds at a slow rate results in several days of delay in establishing full enteral feeds and may increase the risk of invasive infection.
P L A I N L A N G U A G E S U M M A R Y
Slowly advancing milk feeds does not reduce the risk of necrotising enterocolitis in very low birth weight infants
Review question
Does limiting the rate of increase in milk feeds that very low birth weight infants receive each day during the first few weeks after birth reduce the risk of severe bowel problems?
Background
Very low birth weight infants (infants weighing < 1500 grams at birth) are at risk of developing a severe bowel disorder called necrotising enterocolitis (where the bowel becomes inflamed and dies). It is thought that one way to prevent this condition may be to limit the milk feeds that infants receive each day for the first few weeks after birth.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Slow compared with faster rates of enteral feed advancement for preventing necrotising enterocolitis in very preterm or very low birth weight infants Patient or population: very preterm or very low birth weight inf ants Setting: neonatal care f acility Intervention: slow rates of enteral f eed advancem ent Comparison: f aster rates of enteral f eed advancem ent
Outcomes
Anticipated absolute effects* (95% CI) Relative effect (95% CI)
No. of participants (studies)
Quality of the evidence (GRADE)
Comments
Risk with faster rates of enteral feed advancement
Risk with slow rates of enteral feed enhancement
Incidence of necrotising enterocolitis -All inf ants 
B A C K G R O U N D Description of the condition
Necrotising enterocolitis (NEC), a syndrome of acute intestinal necrosis of unknown aetiology, affects about 5% of very preterm (< 32 weeks) or very low birth weight (VLBW) (< 1500 grams) infants (Gagliardi 2008; Holman 1997; Moro 2009 
Description of the intervention
Low gestational age at birth is the major clinical risk factor for developing NEC (Beeby 1992 Evidence shows that feeding with artificial formula rather than human milk increases the risk of developing NEC (Quigley 2014).
Other differences in enteral feeding regimens, such as the timing of introduction of feeds and the size of daily volume increments, may also contribute to inter-unit variation in the incidence of NEC (Chauhan 2008). Multi-centre benchmarking studies have found that neonatal centres where enteral feeding is introduced earlier and feeding volumes are advanced more quickly tend to report higher incidences of NEC (Uauy 1991). Observational studies have suggested that delaying the introduction of enteral feeds beyond the first few days after birth, or increasing the volume of feeds by less than about 20 to 24 mL/kg body weight each day, is associated with lower risk of developing NEC in very preterm or VLBW infants (Brown 1978; Henderson 2009; McKeown 1992; Patole 2005) .
Why it is important to do this review
Potential disadvantages associated with slowing the advancement of enteral feed volumes include delaying establishment of full enteral nutrition and extending the duration of receipt of parenteral nutrition (Flidel-Rimon 2004) . Prolonged use of parenteral nutrition is associated with infectious and metabolic risks that may have adverse consequences for survival, growth, and development (Stoll 2004) . It has been argued that the risk of NEC should not be considered in isolation from these other potential clinical outcomes when feeding policies and practices for very preterm or VLBW infants are determined (Flidel-Rimon 2006; Härtel 2009 ). Other Cochrane reviews have addressed the questions of whether delaying the introduction of any enteral milk feeding or restricting feed volumes to trophic levels (minimal enteral nutrition) affects the risk of NEC in very preterm or VLBW infants (Morgan 2013; Morgan 2014a ). This review focused on the question of whether advancing feed volumes at slow rates compared with faster rates affected risks of NEC, mortality, and other morbidities.
O B J E C T I V E S
To determine effects of slow rates of enteral feed advancement on the incidence of NEC, mortality, and other morbidities in very preterm or VLBW infants.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Controlled trials utilising random or quasi-random participant allocation.
Types of participants
Enterally fed very preterm (< 32 weeks) or VLBW (< 1500 grams) newborn infants.
Types of interventions
Advancement of enteral feeds at no more than 24 mL/kg (birth weight or current body weight) per day versus faster rates of feed advancement. All infants should have received the same type of milk, and in both groups advancement of feed volume should have commenced within five days of introduction of enteral feeds.
Types of outcome measures Primary outcomes
• NEC confirmed at surgery or at autopsy or by at least two of the following features (Walsh 1986) • Abdominal radiograph showing pneumatosis intestinalis or gas in the portal venous system or free air in the abdomen
• Abdominal distension with abdominal radiograph with gaseous distension or frothy appearance of bowel lumen (or both)
• Blood in stool • Lethargy, hypotonia, or apnoea (or a combination of these)
• All-cause mortality during the neonatal period and before hospital discharge
Secondary outcomes
• Growth
• Time to regain birth weight and subsequent rates of weight gain, linear growth, head growth, or skinfold thickness growth up to six months (corrected for preterm birth)
• Long-term growth: weight, height, or head circumference (or proportion of infants who remained below the 10th percentile for the index population's distribution) assessed at intervals from six months of age
• Neurodevelopment • Death or severe neurodevelopmental disability defined as any one or a combination of the following: non-ambulatory cerebral palsy, developmental delay (developmental quotient < 70), auditory and visual impairment. Each component was to be analysed individually and as part of the composite outcome
• Neurodevelopmental scores for survivors aged 12 months or greater measured by validated assessment tools
• Cognitive and educational outcomes among survivors older than five years of age
• Time to establish full enteral feeding (independently of parenteral nutrition)
• Time to establish oral feeding (independently of parenteral nutrition or enteral tube feeding, or both)
• Feed intolerance (defined as a requirement to cease enteral feeds)
• Incidence of invasive infection as determined by culture of bacteria or fungus from blood, cerebrospinal fluid, or urine, or from a normally sterile body space
• Duration of hospital stay (days)
Search methods for identification of studies
We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see the Cochrane Neonatal search strategy for specialized register). 
Electronic searches
Data collection and analysis
We used the standard methods of Cochrane Neonatal ( neonatal.cochrane.org/).
Selection of studies
WM screened titles and abstracts of all records identified by the search and coded records as "order" or "exclude". A second review author assessed all records coded as "order" and made the final decision about which records should be ordered as full-text articles. Two review authors read the full texts and used a checklist to assess each article's eligibility for inclusion on the basis of prespecified inclusion and exclusion criteria.
Data extraction and management
WM and SO extracted data independently using a data collection form to aid extraction of information on design, methods, participants, interventions, outcomes, and treatment effects from each included study. We discussed disagreements until we reached consensus. If data from trial reports were insufficient, we contacted trialists to ask for further information.
Assessment of risk of bias in included studies
Two review authors (WM and SO) independently assessed risk of bias (low, high, or unclear) of all included trials using the Cochrane 'Risk of bias' tool (Higgins 2011) for the following domains.
• Sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Any other bias.
We resolved disagreements by discussion or by consultation with a third assessor. See Appendix 2 for a detailed description of risk of bias for each domain.
Measures of treatment effect
We calculated risk ratio (RR) and risk difference (RD) for dichotomous data and mean difference (MD) for continuous data, with respective 95% confidence intervals (CIs). When we deemed it appropriate to combine two or more study arms, we obtained treatment effects from combined data using the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We determined the number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) for a statistically significant difference in RD.
Unit of analysis issues
The unit of analysis was the participating infant in individually randomised trials. For cluster-randomised trials (had we identified any for inclusion), we planned to undertake analyses at the level of the individual while accounting for clustering in the data by using methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
We requested additional data from trial investigators when data on important outcomes were missing or were reported unclearly. When data remained missing, we examined the impact on effect size estimates by performing sensitivity analyses.
Assessment of heterogeneity
We examined treatment effects in individual trials and heterogeneity between trial results by inspecting forest plots if more than one trial was included in a meta-analysis. We calculated the I² statistic for each analysis to quantify inconsistency across studies and to describe the percentage of variability in effect estimates that may be due to heterogeneity rather than to sampling error. If we detected moderate or high (I² > 50%) levels of heterogeneity, we explored possible causes (e.g. differences in study design, participants, or interventions; completeness of outcome assessments) by performing sensitivity analyses.
Data synthesis
We used a fixed-effect model for meta-analyses.
Quality of evidence
We used the GRADE approach, as outlined in the GRADE Handbook (Schünemann 2013), to assess the quality of evidence for the following (clinically relevant) outcomes: incidence of NEC, mortality, feed intolerance, and invasive infection. Two review authors independently assessed the quality of the evidence for each of the outcomes above. We considered evidence from RCTs as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations on the basis of the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates, and presence of publication bias. We used the GRADEpro GDT Guideline Development Tool to create a 'Summary of findings' table to report the quality of the evidence. The GRADE approach results in assessment of the quality of a body of evidence according to one of four grades. 1. High: We are very confident that the true effect lies close to that of the estimate of the effect.
2. Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
3. Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
4. Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses.
• Trials in which most infants were exclusively formula-fed.
• Trials in which most infants were at least partially fed with human milk (maternal or donor).
• Trials in which most participants were of extremely low birth weight (ELBW) (< 1000 g) or extremely preterm gestational age (< 28 weeks).
• Trials in which participants were infants with intrauterine growth restriction.
• Infants with absent or reversed end-diastolic flow velocities detected on antenatal Doppler studies of the foetal aorta or umbilical artery. All trials specified participant birth weight eligibility criteria.
R E S U L T S Description of studies
• Rayyis 1999: < 1500 grams.
• Caple 2004: 1000 to 2000 grams.
• Salhotra 2004: < 1250 grams.
• Krishnamurthy 2010: 1000 to 1500 grams.
• Karagol 2013: 750 to 1250 grams.
• Jain 2016: 1000 to 1249 grams.
• Raban 2014a: < 1001 grams.
• Raban 2014b: < 1001 grams.
• Modi 2015: 750 to 1250 grams.
• SIFT 2016: < 1500 grams.
Most participants in Caple 2004
and Jain 2016 were of birth weight less than 1500 grams or gestational age less than 32 weeks; therefore, we made a consensus decision to include these trials. Infants born 'small for gestational age' (birth weight < 10th percentile of the index population distribution) were not eligible to participate in Caple 2004 but were included in the other trials. More than 95% of participants in Salhotra 2004 were small for gestational age. One-third of participants in Karagol 2013 were ELBW infants. All participants in Jain 2016 had antenatal evidence of absent or reversed end-diastolic flow.
Interventions and comparisons
All trials commenced interval bolus intragastric feeding typically within the first seven days after birth. Infants were randomly allocated to one of two rates of daily increments in enteral feed volume.
• Rayyis 1999: 15 versus 35 mL/kg.
• Caple 2004: 20 versus 35 mL/kg.
• Salhotra 2004: 15 versus 30 mL/kg.
• Krishnamurthy 2010: 20 versus 30 mL/kg.
• Karagol 2013: 20 versus 30 mL/kg.
• Jain 2016: 20 versus 30 mL/kg.
• Raban 2014a: 24 versus 36 mL/kg.
• Raban 2014b: 24 versus 36 mL/kg.
• Modi 2015: 15 to 20 versus 30 to 40 mL/kg.
• SIFT 2016: 18 versus 30 mL/kg.
In one trial, only formula-fed infants were eligible to participate (Rayyis 1999). In Caple 2004 , Jain 2016 , Karagol 2013 , Krishnamurthy 2010 , Modi 2015 , and SIFT 2016 , infants received expressed breast milk or formula, or a combination. In Raban 2014a, Raban 2014b, and Salhotra 2004, participating infants were fed exclusively with expressed breast milk. Most trial protocols specified indications for interrupting or ceasing enteral feeding, such as residual gastric contents of more than about onethird of the previous feed volume, frequent vomiting, abdominal distension, or detection of blood in the stools (including occult blood). SIFT 2016 did not prespecify these criteria but allowed clinicians and caregivers to apply unit-specific policies and practices.
Outcomes
All trials reported the incidence of NEC confirmed radiologically or at surgery or at autopsy. Other reported outcomes included time to regain birth weight, time to establish full enteral feeding, duration of hospital stay, and rates of invasive infection.
Excluded studies
We excluded 
Risk of bias in included studies
The methodological quality of the included trials was generally good (Figure 2 ). All trials employed methods to ensure adequate allocation concealment and reported complete or near-complete assessments of primary outcomes. None of the included trials were able to conceal feeding strategies from parents, caregivers, or clinical investigators. Three studies clearly masked assessment of abdominal radiographs (for diagnosis of NEC). In Karagol 2013 , Modi 2015 , Raban 2014a , Raban 2014b , Salhotra 2004 , and SIFT 2016 , it remains unclear whether precautions had been taken to ensure that radiological assessors were blinded to the allocation group. 
Effects of interventions
See: Summary of findings for the main comparison Slow compared with faster rates of enteral feed advancement for preventing necrotising enterocolitis in very preterm or very low birth weight infants
Primary outcomes Incidence of necrotising enterocolitis
Meta-analysis did not show an effect on the risk of NEC (typical RR 1.07, 95% CI 0.83 to 1.39; RD 0.00, 95% CI -0.01 to 0.02; 10 studies, 3742 infants; I² = 21%) (Analysis 1.1; Figure 3 ). The funnel plot did not indicate small study or publication bias ( Figure  4 ). 
Subgroup analyses did not show an effect in:
• trials where most infants were exclusively formula-fed: RR 1.44 (95% CI 0.63 to 3.32); RD 0.04 (95% CI -0.05 to 0.13); one study (Rayyis 1999), 185 infants;
• trials where most infants were at least partially fed with human milk: RR 1.04 (95% CI 0.79 to 1.37); RD 0.00 (95% CI -0.01 to 0.02); nine studies (all except Rayyis 1999), 3557 infants; I² = 26%;
• extremely preterm or ELBW infants: RR 1.01 (95% CI 0.74 to 1.38); RD 0.00 (95% CI -0.03 to 0.03); five studies, 1299 infants; I² = 59% ( Figure 3 );
• infants with intrauterine growth restriction: RR 1.26 (95% CI 0.67 to 2.37); RD 0.01 (95% CI -0.02 to 0.05); two studies, 639 infants; I² = 36% ( Figure 3) ; or • infants with evidence of absent or reversed end-diastolic flow velocity (AREDFV): RR 1.59 (95% CI 0.74 to 3.40); RD 0.03 (95% CI -0.02 to 0.07); two studies, 465 infants; I² = 10% (Figure 3) .
Mortality
Meta-analysis did not show an effect on risk of mortality (typical RR 1.15, 95% CI 0.93 to 1.42; RD 0.01, 95% CI -0.01 to 0.03; nine studies, 3576 infants; I² = 13%) (Analysis 1.2; Figure 5 ). 
Subgroup analyses did not show an effect in:
• trials where most infants were exclusively formula-fed: RR not estimable (no deaths in either group); RD 0.00 (95% CI -0.02 to 0.02); one study (Rayyis 1999), 185 infants;
• trials where most infants were at least partially fed with human milk: RR 1.15 (95% CI 0.93 to 1.42); RD 0.01 (95% CI -0.01 to 0.03); eight studies (all except Rayyis 1999), 3391 infants; I² = 13%;
• 
Secondary outcomes Growth
Seven trials reported that infants in the slow-rate-of-advancement group took a longer time to regain birth weight.
• Rayyis 1999: median difference 2 days.
• Caple 2004: MD 2 days (95% CI 1 to 3).
• Salhotra 2004: median difference 5 days.
• Krishnamurthy 2010: median difference 6 days.
• Karagol 2013: MD 3.8 days (CI not given).
• Raban 2014a: data not available.
• Raban 2014b: data not available.
Jain 2016 and Modi 2015 did not report growth. SIFT 2016 did not show any statistically significant differences in weight (MD 0.00, 95% CI -0.08 to 0.08) nor in head circumference (MD 0.00, 95% CI -0.13 to 0.13) z-scores at hospital discharge (Analysis 1.3; Analysis 1.4).
None of the included trials have yet reported post-hospital discharge growth parameters.
Neurodevelopment
None of the trials have yet reported neurodevelopmental outcomes.
Time to establish full enteral feeding
Seven trials reported that it took longer to establish full enteral feeds in infants in the slow-rate-of-advancement group.
• Rayyis 1999: median difference 4 days.
• Caple 2004: MD 3 days (95% CI 2 to 3).
• Salhotra 2004: MD 4.8 days (CI not given).
• Krishnamurthy 2010: median difference 2 days.
• Karagol 2013: MD 3.2 days (CI not given).
• Jain 2016: MD 0.6 days (CI not given).
• Modi 2015: MD 4 days (CI not given).
• SIFT 2016: median difference 3 days.
Raban 2014a and Raban 2014b did not report this outcome.
Time to establish full oral feeding
None of the trials reported time to establish full oral feeding.
Feed intolerance (causing interruption of enteral feeding) (Outcome 1.5)
Meta-analysis of data from seven trials (659 infants) did not show a difference (typical RR 1.20, 95% CI 0.95 to 1.50; typical RD 0.05, 95% CI -0.02 to 0.12; I² = 0%) (Analysis 1.5; Figure 6 ). Meta-analysis of data from seven trials (3392 infants) showed borderline higher risk among infants who received slow advancement of enteral feed volumes (typical RR 1.15, 95% CI 1.00 to 1.32; typical RD 0.03, 95% CI -0.00 to 0.05; I² = 0%) (Analysis 1.6; Figure 7 ). Incidence of invasive infection.
Duration of hospital stay
Four trials did not show a statistically significant difference in duration of hospital stay.
• Caple 2004: MD 5 days (95% CI -1 to 8).
• SIFT 2016: median difference 0 days (54 vs 54 days).
Two trials reported that duration of hospital stay was longer among infants in the slow-rate-of-advancement group.
• Krishnamurthy 2010: median difference 1.5 days.
• Karagol 2013: MD 6 days (CI not given).
The other trials did not report duration of hospital stay (Jain 2016; Modi 2015; Salhotra 2004).
D I S C U S S I O N
Summary of main results
Available trial data do not provide evidence that advancing enteral feed volumes at slow rates (15 to 20 mL/kg/d) compared with faster rates (30 to 40 mL/kg/d) reduces the risk of necrotising enterocolitis (NEC) in very low birth weight (VLBW) infants. The boundaries of the 95% confidence interval (CI) for the estimate of effect are consistent with either two extra or one fewer cases of NEC in every 100 infants who have slow rates of feed advancement. Meta-analysis of data from these trials did not show an effect on all-cause mortality, and prespecified subgroup analyses revealed no statistically significant effects on risk of NEC or death among extremely low birth weight (ELBW) or extremely preterm infants, nor among infants with growth restriction or evidence of absent or reversed end-diastolic flow velocity (AREDFV). Meta-analysis of data from eight trials showed borderline higher risk of late-onset infection among infants who had slow advancement of enteral feeds. The point estimate suggested that an extra episode of lateonset infection occurs for every 33 infants who have slow feed advancement.
Infants who had slow advancement of feed volumes established full enteral feeding and regained birth weight several days later than infants who had faster rates of advancement of feed volumes. The clinical importance of these effects is unclear, as longer-term growth or developmental outcomes were not assessed. The included trials did not show consistent evidence of an important effect on duration of hospital admission.
Overall completeness and applicability of evidence
Most participants in the included trials were stable very preterm or VLBW infants of birth weight appropriate for gestational age. About one-third of all participants were extremely preterm or ELBW, and about one-fifth were small for gestational age, growthrestricted, or compromised in utero, as indicated by AREDFV in the foetal umbilical artery. Infants who had severe respiratory distress requiring oxygen supplementation or ventilatory support were eligible to participate in all but three of the trials (Karagol 2013; Krishnamurthy 2010; Salhotra 2004 
Quality of the evidence
The GRADE quality of evidence for primary outcomes was "moderate", downgraded from "high" because of lack of blinding in the included trials (Summary of findings for the main comparison). Although these trials were generally of good methodological quality, in common with other trials of feeding interventions in this population, it was not possible to mask caregivers and clinical assessors to the nature of the intervention (Figure 2 ). Lack of blinding may have resulted in surveillance and ascertainment biases. It is more likely, however, to have caused an overestimation of the incidence of feed intolerance and NEC among infants whose feed volumes were advanced faster. Assessment of abdominal radiographs for signs of NEC was masked in most trials to ensure that the diagnosis of severe NEC (confirmed by radiological detection of gas in the bowel wall or portal tract) was not prone to bias. However, as microbial generation of gas in the bowel wall is substrate dependent, infants who received more enteral milk (substrate) may have been more likely to demonstrate this radiological sign than infants with equally severe bowel disease who had less intraluminal substrate. This 'substrate effect' is also more likely to cause over-ascertainment of NEC among infants who had faster rates of feed volume advancement (Tyson 2007).
Potential biases in the review process
The main concern with the review process is the possibility that findings are subject to publication and other reporting biases. We attempted to minimise this threat by screening the reference lists of included trials and related reviews and searching the proceedings of major international perinatal conferences to identify trial reports that are not (yet) published in full form in academic journals. Only one of the meta-analyses that we performed included sufficient trials to explore symmetry of funnel plots as a means of identifying possible publication or small study bias, and this did not show sufficient asymmetry to raise concerns (Figure 3 ).
Agreements and disagreements with other studies or reviews
This review focused specifically on the comparison of slow versus faster rates of feed volume advancement and did not compare progressive advancement with enteral fasting or trophic feeding (minimal enteral nutrition). Only one randomised controlled trial has compared trophic feeding with progressive enteral feed volume advancement (at daily increments of 20 mL/kg) (Berseth 2003) . Although this trial found the risk of NEC to be statistically significantly higher among infants whose feed volumes were progressively advanced, this finding should be interpreted cautiously. The trial was stopped early following an interim analysis; therefore, the finding of an effect on the incidence of NEC may be spurious (Montori 2005). Caregivers and assessors were not blinded to the intervention. As discussed above, this may have resulted in several sources of bias that are likely to cause an overestimation of the incidence of NEC among infants whose feed volumes are being advanced.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Advancing enteral feed volumes at slow rates (slower than 24 mL/ kg/d) does not reduce the risk of feed intolerance, NEC, or death in very preterm or VLBW infants, including extremely preterm or ELBW infants, or in infants who are growth-restricted or growthcompromised in utero. Advancing the volume of enteral feeds at faster rates (daily increments of 30 to 40 mL/kg) shortens by several days the time taken to regain birth weight and establish full enteral feeds, and may reduce the risk of late-onset invasive infection.
Implications for research
Additional randomised controlled trials are unlikely to alter these effect estimates for feed intolerance, NEC, or death. Data on longer-term outcomes, principally growth and development beyond infancy, may be available from the largest of the existing completed trials when follow-up assessment has been completed.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Low risk 3 infants excluded after enrolment because of protocol violations were included in this review and meta-analysis. 2 infants (1 in each group) were excluded because they were determined not eligible for enrolment as the result of an in utero gastrointestinal perforation and foetal alcohol syndrome; these infants were not included in the metaanalysis 
Risk of bias
